Results 101 to 110 of about 465,548 (350)

Multimodal Image Analysis of Chronic Leukemic Lymphoproliferative Disorders and the Hypothesis of »Single« and »Multiple« Programmed Stops in the Development of Typical and Atypical Forms of Leukemias and Lymphomas [PDF]

, 2010
The study consisted of morphometric analysis, assessment of the argyrophilic nucleolar organization region (AgNOR) characteristics, and image cytometry (ICM) in different tumor mass compartments: bone marrow (BM), peripheral blood (PB) and lymph nodes ...
Biljana Jelić Puškarić, Branimr Jakšić, Delfa Radić-Krišto, Ika Kardum-Skelin, Matko Kardum, Ozren Jakšić   +5 more
core   +2 more sources

A preclinical model for the ATLL lymphoma subtype with insights into the role of microenvironment in HTLV-1-mediated lymphomagenesis [PDF]

, 2018
\uef7f View references (83) Adult T cell Leukemia/Lymphoma (ATLL) is a mature T cell malignancy associated with Human T cell Leukemia Virus type 1 (HTLV-1) infection.
Adriana Mattiolo, Alberto Amadori, Alberto Amadori, Barbara Montini, Ilaria Cavallari, Luigi Chieco-Bianchi, Maria Assunta Piano, Maria Luisa Calabrò, Mattia Vicario   +8 more
core   +2 more sources

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma

Journal of the Advanced Practitioner in Oncology, 2015
Peripheral T-cell lymphomas (PTCLs) are a rare, heterogeneous group of T-cell– or natural killer cell–derived non-Hodgkin lymphomas. The majority of patients with PTCL experience an aggressive disease course and poor overall survival.
Lisa Barbarotta, K. Hurley
semanticscholar   +2 more sources

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. [PDF]

, 1992
Engagement of the CD3/T cell antigen receptor complex on small, resting T cells is insufficient to trigger cell-mediated cytotoxicity or to induce a proliferative response.
Azuma, M, Buck, D, Cayabyab, M, Lanier, LL, Phillips, JH   +4 more
core   +1 more source

Clinicopathological features of extranodal lymphomas: Kuwait experience [PDF]

, 2004
A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and ...
Bamanikar S, D'Amore F, Ducreux M, F. Sinowatz, Freeman C, Gospodarowicz MK, H. Amanguno, H. Baker, Hauke RJ, J.P. Madda, L. Temmim, Longo DL, Neugut AI, Penn I, Shome DK, Stiller CA, Weisenburger DD, Zeeb H   +17 more
core   +1 more source

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy

Journal for ImmunoTherapy of Cancer, 2020
Background Tumor relapse due to mutation in CD19 can hinder the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Herein, we focused on lymphoma patients whose B cells exhibited a point mutation in CD19 of B cells after CAR-T cell infusion ...
Zhen Zhang, Xinfeng Chen, Yonggui Tian, Feng Li, Xuan Zhao, Jinyan Liu, C. Yao, Yi Zhang   +7 more
semanticscholar   +1 more source

Peripheral T-cell lymphoma: novel backbone [PDF]

Blood, 2018
In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL ...
openaire   +2 more sources

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

Advanced Science, EarlyView.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang, Weijiao Xu, Lei Zhao, Lin Zhong, Wendan Yu, Shengmin Wang, Lu Sun, Tao Guo, Fengzhou Li, Zhuoshi Li, Lei Fang, Shiqing Wang, Guohui Zhang, Guoqing Xue, Wei Guo, Shilei Zhao, Chundong Gu   +16 more
wiley   +1 more source

Intraclonal diversity in a Sezary syndrome with a differential response to 2‐deoxycoformycin of the two lymphoma cell populations [PDF]

, 2002
Br J Haematol. 2002 Dec;119(3):629-33. Intraclonal diversity in a Sezary syndrome with a differential response to 2-deoxycoformycin of the two lymphoma cell populations.
BALANZATEGUI, A., CANDEIAS, J., CUNHA, N., GRANJO, E., LIMA, M., LOPES, J.M., MATUTES, E., ORFAO, A., RESENDE, C., SANTOS, A.H., SANTOS, F., TEIXEIRA, M. A.   +11 more
core   +1 more source